Viralytics' P2P Acquisition

Viralytics raised a round of funding on February 21, 2018. Investors include Merck & Co..

Viralytics is focused on the development and commercialization of oncolytic immunotherapies that harness the power of certain viruses to preferentially infect and kill cancer cells.…

Articles about Viralytics' P2P Acquisition: